Citations (0)
Keep up to date with the latest research on this topic with citation updates for this article.
Letter to the Editor
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy
Tara Cochranea Department of Haematology, Gold Coast University Hospital, Southport, Australia;b School of Medicine, Griffiths University, Parkwood, Queensland, AustraliaCorrespondence[email protected]
https://orcid.org/0000-0002-2668-1399View further author information
https://orcid.org/0000-0002-2668-1399View further author information, Alicia Enricoc Area Hematology, Hospital Italiano La Plata, Buenos Aires, Argentinahttps://orcid.org/0000-0002-1983-6145View further author information
https://orcid.org/0000-0002-1983-6145View further author information, David Gomez-Almaguerd Hematology Service, Hospital Universitario, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexicohttps://orcid.org/0000-0002-0460-6427View further author information
https://orcid.org/0000-0002-0460-6427View further author information, Evgueniy Hadjieve Department of Internal Medicine, Medical University Sofia, University Hospital Alexandrovska, Sofia, Bulgariahttps://orcid.org/0000-0002-7811-6965View further author information
https://orcid.org/0000-0002-7811-6965View further author information, , Tamas Masszig Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungaryhttps://orcid.org/0000-0003-2322-9863View further author information
https://orcid.org/0000-0003-2322-9863View further author information, Eugene Nikitinh Department of Hematology, Oncology and Chemotherapy, S. P. Botkin’s City Hospital, Moscow, Russiahttps://orcid.org/0000-0002-2490-1263View further author information
https://orcid.org/0000-0002-2490-1263View further author information, Tadeusz Robaki Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Polandhttps://orcid.org/0000-0002-3411-6357View further author information
https://orcid.org/0000-0002-3411-6357View further author information, Robert Weinkovej Te Rerenga Ora Wellington Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast & Hutt Valley, Wellington, New Zealand;k Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealandhttps://orcid.org/0000-0003-3645-7988View further author information
https://orcid.org/0000-0003-3645-7988View further author information, , Beenish S. Manzoorm AbbVie, Inc., North Chicago, IL, USAhttps://orcid.org/0000-0002-0329-3465View further author information
https://orcid.org/0000-0002-0329-3465View further author information, , , & Mary Ann Andersono The Clinical Haematology Department of the Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Victoria, Australia;p Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Parkville, Victoria, Australiahttps://orcid.org/0000-0002-3515-0215View further author information
https://orcid.org/0000-0002-3515-0215View further author information show all